An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes

摘要

The main purpose of the present study is to evaluate whether treatment with long-acting human glucagon-like peptide-1 liraglutide was associated with an improvement of excessive daytime sleepiness (EDS) in obese subjects with type-2 diabetes. This single-centre retrospective study included 158 obese (body mass index [BMI]?≥?30?kg/m2) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3?months before study inclusion. Data of the Epworth Sleepiness Scale (ESS), anthropometric parameters, glucose-control and metabolic parameters were collected at liraglutide initiation (baseline) and at months 1 and 3 after liraglutide initiation. Significant reductions in ESS score were achieved at months 1 (?1.3?±?2.8, p?